The Preparation and Biocompatibility Study on Fe_2O_3 Magnetic Nanoparticles Used in Tumor Hyperthermia

Objective：To evaluate the in vitro and in vivo toxicity of self-prepared nanosized Fe2O3, which has the potential implication in tumor hyperthermia. Methods： Fe2O3 nanoparticles were prepared by improving co-precipitation, which characterization was detected by TEM, XRD, CMIAS, EDS. MTT assay was used to evaluate the in vitro cytotoxicity test; hemolytic test was carried out to estimate whether it has blood toxicity; Fe2O3 suspended in sterile 0.9% NaCl was intraperitoneally injected into Kumning mouse to calculate the LD50 ; micronucleus （MN） were reckoned to identify whether it is genotoxic. Results：The nanoparticles are brown spherical particles with diameter ranging from 8 to 15 nm, which have good decentralization and stability. The experiments also showed that the toxicity of the material on mouse fibroblast （L-929） cell lines was 0 - 1 degree ; it has no hemolysis activity; LD50 arrived at 5.45 g/kg^-1 after intraperitoneal injection of 1 ml suspension; micronucleus test showed that it has no genotoxic effects either. Conclusion： The results showed that the Fe2O3 nanoparticles are prepared successfully, the self-prepared nanosized Fe2O3 is a kind of high biocompatibility materials and perhaps it is suitable for further application in tumor hyperthermia.

Rhabdomyosarcoma of the breast： a clinicopathologic study and review of the literature

Background Rhabdomyosarcoma （RMS） is an uncommon malignancy of the breast. The aim of this study was to summarize its clinicopathologic features and biological behavior. Methods Five primary or secondary breast RMSs were collected. Their clinicopathological characteristics and all published literature about breast RMS were reviewed. Immunohistochemical study of desmin, myogenic differentiation 1 （MyoD1）, myogenin, leukocyte common antigen （LCA）, vimentin, cytokeratin （AEI/AE3）, E-cadherin, neuron specific enolase （NSE）, CD99, chorioallantoic membrane 5.2 （CAM5.2） and epithelial membrane antigen （EMA） expression were performed. Results The five patients were all female with ages ranging from 16 to 46 years old （mean, 30 years）. Three were metastatic breast RMSs, two embryonal and one solid variant alveolar, with the primary tumor sites the right labium majus, left nasal meatus and nasopharynx, respectively. The other two, one embryonal and one alveolar, were primaries. Grossly, the surgical specimens revealed round or oval, well-demarcated but nonencapsulated masses. Their cut surfaces consisted of homogeneous grayish yellow or white tissue. Microscopically, most tumor cells were poorly differentiated small round, oval or small polygons with eosinophilic cytoplasm. All cases were positive for vimentin, desmin, MyoD1 and myogenin. One embryonal RMS also had a few cells with perinuclear staining of AEI/AE3. The other markers were negative. Conclusions Although primary or metastatic RMS in breast was almost confined to young adolescent females, our cases suggested that it can also happen to the middle-aged women. Embryonal RMS has a certain metastatic potential. MyoD1 and myogenin are two useful markers when making differential diagnosis. Axillary lymph node status and age may play a role in the prognosis of primary breast RMS patients.